eligibility checklist

Funds Available

View the full list of funds available

Read more
eligibility checklist

What type of finance do I need?

Our online eligibility checklist helps you see which type of finance might be right for your business.

Read more
23 July 2014

The North West Fund for Biomedical investee companies pitch at UKBAA Investment Summit

News article

Four investee companies from The North West Fund for Biomedical took part in a pitching event as part of this year's UK Business Angel Association's Investment Summit.

Tomorrows Medicines, Videregen, Gelexir Healthcare and Alchemy PharmaTech were amongst a number of companies selected to pitch in front of high profile investors and business angels.

The event took place at St George's Hall, Liverpool, and was part of the much anticipated two day UKBAA Investment Summit earlier this month.

Managed by SPARK Impact, The North West Fund for Biomedical is a sub-fund of The North West Fund which is financed by the European Regional Development Fund and the European Investment Bank. Companies from the SPARK Impact portfolio, including Handsome, Sky Medical, Incanthera, EnXray, Albert Medical Devices and Bioxydyn, were also involved in a showcase of the top 20 North West 'Ones to Watch' at the event which was the UK's largest angel-investor gathering.

Dr. Andy Round, investment director at SPARK Impact and fund manager for The North West Fund for Biomedical, kicked off the pitching event with an introduction highlighting the importance of the life sciences sector, stating it represents around 4,500 companies, employing more than 166,000 staff and making £50bn annually equating to around £10bn in Liverpool.

The first SPARK Impact investee company to take to the stage was Tomorrows Medicines which is a digital platform to recruit patients for clinical trials. Dr Clare Nolan of Tomorrows Medicines said that around 40 per cent of clinical trials fail to complete because of a lack of patients and therefore www.yourtreatmentchoices.com was created to assist in solving the problem.

Up next was Dr Steve Bloor from Videregen who detailed the tissue engineering technology which enables windpipe (trachea) replacements. Dr Bloor said: "Regenerative medicine is a rapidly growing field and we hope our world-leading technology will have a big impact on organ transplantation in future."

The audience then heard from Hans von Celsing, executive director of Gelexir Healthcare which has developed a non-surgical procedure for the treatment of chronic lower back pain caused by degenerative disc disease.

The last pitch to investors was from Ian Harrison of Alchemy PharmaTech. Mr Harrison presented two drug delivery platforms which provide unit-dose, needle-free intranasal delivery of nasal pain relief which is quickly absorbed into the blood stream.

Several SPARK Impact investee companies were also shortlisted in the 2014 Angel Investment Awards which took place on Tuesday 1st July at Liverpool Cathedral.

Albert Medical Devices, TTS Pharma, Gelexir Healthcare, Sky Medical and Videregen all attended the gala black-tie awards dinner which featured guest speakers, Max Steinberg, Liverpool Vision and Sir Terry Leahy. 

 

 


Back to article list